A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes (SURPASS J-mono)
The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 636 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
Actual Study Start Date: May 7, 2019
Estimated Primary Completion Date: April 17, 2021
Estimated Study Completion Date: April 17, 2021
Arms:
- Experimental: 5 mg Tirzepatide
- Experimental: 10 mg Tirzepatide
- Experimental: 15 mg Tirzepatide
- Active Comparator: 0.75 mg Dulaglutide
| Category | Value |
|---|---|
| Date last updated at source | 2019-07-03 |
| Study type(s) | Interventional |
| Expected enrolment | 636 |
| Study start date | 2019-05-07 |
| Estimated primary completion date | 2021-04-17 |